XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 25.33

-1.9%

Dec 17 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Olu Emuleomo who started this subject	6/24/2002 11:30:39 AM
From: aknahow	of 17367

Robert KK or anyone, why would any partner begin clinical trials with a drug produced by the the partner that would not be responsible for final production if approval is ultimately obtained? One could argue that P I and P II are so small that the issue would only arise on P III trials. I accept this. Baxter's next indication for Neuprex is apparently going to be sepsis. Probably will start as a P II trial.. Since meningococcemia is a form of sepsis, there is a small chance the trial could start at P III. The data from the meningococccemia trial is available to Baxter. Xoma will do better if it is producing the Neuprex as all development expenses are paid by Baxter. Instead of being any drain on cash or income the trial will be neutral or a plus if Xoma product is used. Hope the sepsis news if finalized sometime in July.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next